Stifel: Maintaining the Iridex (IRIX.US) rating, adjusted from holding to holding, with a target price of $2.00.
Iridex Analyst Ratings
Stifel Maintains Hold on Iridex, Maintains $2 Price Target
Analysts Offer Insights on Healthcare Companies: Iridex (IRIX), Nyxoah (NYXH) and Enliven Therapeutics (ELVN)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX), Iridex (IRIX) and Keros Therapeutics (KROS)
Stifel Nicolaus Sticks to Its Hold Rating for Iridex (IRIX)
No Data
No Data